Innovations from Pharmapack Europe Exhibitors
On February 15-16 in Paris, Pharmapack Europe will host more than 250 leading companies involved in the design, manufacture, and supply of drug-delivery systems and pharmaceutical and medical packaging.
We explore some of their latest news and innovations below. For a complete list of exhibitors, visit www.pharmapack.fr.
STORY CONTINUES BELOW
Gerresheimer's new multilayer plastic vials have been honored in the Retail Packaging category of the German Packaging Awards 2011, by the Federal Ministry of Economics and Technology. The new multilayer vials feature a triple-layer structure consisting of a layer of polyamide sandwiched between two Cyclic Olefine Polymer (COP) layers. According to the company, COP has already been proven to be compatible with biotechnologically manufactured pharmaceuticals that have complex molecular structures. The polyamide layer functions as an oxygen barrier, resulting in a 40 times reduction of oxygen transmission compared with conventional plastic type vials. The absence of heavy metal ions increases the stability of oxidation-sensitive solutions and an inert surface minimizes possible interactions.
In addition, the triple-layer structure offers shock resistance. Gerresheimer reports that multilayer vials have far higher break resistance than glass vials and are therefore the ideal packaging for parenteral medications with a wide pH range. The multilayer composite of COP and polyamide even prevents leakage of the solution when the external COP layer is damaged.
Standard rubber closures and flanged caps can be used. Gerresheimer also states that materials used fulfill the stringent requirements for biocompatibility and all pharmacopeia requirements for pharmaceutical packaging made of plastic.
Schreiner Group GmbH & Co. KG
Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for 60 years, has developed a new label with integrated covert inscriptions designed to help eliminate the illegal practice of empty vials being refilled with fake drugs and resold. The new Pharma-Comb Void label prevents the reuse of authentic packaging components by counterfeiters and thus increases the product safety of medications while protecting patients against the administration of ineffective or harmful counterfeit drugs.
Stiplastics has introduced in-mold labeling technology for producing indelible images and text on dosage devices. Employing no secondary operations, the company places preprinted labels inside molds for a dosing cups, droppers, spoons, cases, or other components and injects plastic into the mold. Adaptable to all shapes and sizes, the process is highly controlled in order to produce an accurate measuring device. Graduations do not fade or wear over time, the company claims. Dosing cups can be designed to snap onto bottles for a secure fit. Stiplastics is a French company with a 25-year history of designing, developing, manufacturing, and selling injected plastic based technical products and innovative plastics devices mainly for the pharmaceutical and health industry.
Catalent Pharma Solutions
Catalent continues to expand its technologies and capabilities globally. Its new analytical services lab at Sindon, UK, is designed to meet regulatory requirements in the European Union, United States, and other markets. Initial capabilities include raw materials and finished product release testing; qualified person release; method development and validation; compendial testing; microbiology; stability testing and storage.
Catalent is also working with Sanwa Pharmaceuticals and Pantec AG for the global launch of OSDrC OptiDose flexible modified release delivery, and Lyopan fast-dissolve technology, respectively. In addition, the pending addition of Aptuit's clinical trials supplies and pharmaceutical development and manufacturing operations will make Catalent a global leader in clinical trial solutions.
TEKNIplex Europe N.V.
Tekni-Plex now offers blister films containing PCTFE Aclar UltRx6000 thermoform film for high barrier against moisture. The 6-mil (152.4-micron) PCTFE film can be laminated to a variety of substrate materials including PVC, PP, COC, PETG, PE, and EVOH resulting in several innovative structures that offer improvements in moisture barrier of up to 71% compared to PVC/UltRx4000 laminates on the market today.
Bilcare Research offers Bilcare Protect, a specialty pharmaceutical grade blister film designed to fight counterfeiting with embedded images that are nearly impossible to duplicate. Employing a precise amount of metal deposition which, in turn, is embedded with images and patterns, creates a unique differential grating methodology. The result is a non-replicable blister package pattern – one that is permanent and does not get damaged or erased even with high-temperature or high-pressure applications, or during post-packaging storage.
Constantia Hueck Foils offer anti-counterfeiting security foils; push-through and peelable blister foils; cold-formable foils for absolute barrier to moisture and oxygen; heat seal coatings for PVC, PVdC, Aclar laminations, PET, PP and Barex; two-sided registered printing for compliance-style packaging; text and bar code-printable white lacquered foils; high-slip lidding and capping foil; plus child-resistant and senior-friendly structures. In addition, Constantia Hueck's Pharma Finishing Services Program provides quick turnaround for customers who require materials for clinical trials, stabilities, and other special needs. Specific product details and photos are available upon request.
Clondalkin Pharma & Healthcare
Clondalkin Pharma & Healthcare Ireland announces that it will consolidate from its present three production sites in Dublin to two production sites by absorbing the Clonshaugh facility into the Glasnevin and Cherry Orchard facilities.
David Lennon, CEO of Clondalkin Pharma & Healthcare, said in a statement: "Consolidating our Dublin activities from three sites to two sites is a strong and positive development in our continuous business improvement strategies. It will move our Dublin businesses to the next level in delivering market leading innovative products and services to our customers."
The three Dublin sites are close in proximity, and they share platforms in products, technologies, and customer markets, added Lennon. Production will be enhanced by streamlining and combining production activities to increase capacity utilization. "We are backing the new configuration with significant investments in new digital print technologies and in upgrading our facilities at Glasnevin and Cherry Orchard," he added.
The Dublin businesses will continue to supply existing markets and customers in institutional, commercial, and pharmaceutical and healthcare markets. Capabilities include design, prepress, printing, finishing, and delivery. The Cherry Orchard site was recently awarded the PS9000:2011 accreditation, the first such accreditation awarded globally.
Back to Home